07:16 AM EDT, 05/13/2026 (MT Newswires) -- Astrazeneca (AZN) signed a three-year licensing agreement with Owkin to develop biopharma AI agents using Owkin's K Pro platform for drug development and decision-making, Owkin said Wednesday.

Under the agreement, Owkin said it will develop and deploy AI agents within AstraZeneca's IT systems and workflows to support competitive intelligence and data-driven decision making across the biopharma value chain.

Ämnen i artikeln

AstraZeneca

Senast

1 737,00

1 dag %

1,05%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån